GlassScriptPhysician profile
Akash Mukherjee
NPI 1285981498
$131,798.47
in general payments reported to CMS, 2019-2025
36 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2021: $4,614 · 2022: $5,762 · 2023: $59K · 2024: $25K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Travel and Lodging: $5,209 · Food and Beverage: $3,494 · Consulting Fee: $2,525 · Education: $37.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,045.00 |
| Travel and Lodging | $5,208.98 |
| Food and Beverage | $3,494.25 |
| Consulting Fee | $2,525.00 |
| Education | $37.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $74,083.62 | 2021-2025 | Yescarta |
| Beigene USA, INC. | $41,470.14 | 2023-2024 | Brukinsa |
| Beone Medicines USA, INC. | $10,890.53 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $3,718.85 | 2023 | |
| Astellas Pharma US INC | $282.22 | 2021-2025 | Cresemba, Vyloy |
| Novartis Pharmaceuticals Corporation | $139.86 | 2024-2025 | |
| Abbvie INC. | $113.29 | 2024-2025 | |
| Janssen Biotech, INC. | $112.11 | 2025 | Darzalex, Talvey, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $111.81 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $92.41 | 2024-2025 | Sancuso |
| Daiichi Sankyo INC. | $88.22 | 2025 | Vanflyta |
| Glaxosmithkline, LLC. | $86.11 | 2025 | Ojjaara, Blenrep |
| Pfizer INC. | $73.75 | 2025 | |
| Sanofi-Aventis U.S. LLC | $62.85 | 2025 | |
| Azurity Pharmaceuticals, INC. | $47.31 | 2025 | Vivimusta, Danziten |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $43.89 | 2025 | Jakafi, Niktimvo, Niktimvo |
| Invivyd INC | $41.82 | 2025 | Pemgarda |
| Genentech USA, INC. | $38.41 | 2025 | Venclexta, Polivy |
| Shorla Oncology INC. | $33.50 | 2025 | |
| Syndax Pharmaceuticals, INC. | $32.59 | 2025 | |
| Genzyme Corporation | $30.91 | 2025 | |
| Adaptive Biotechnologies Corporation | $29.95 | 2025 | Clonoseq |
| Sobi, INC | $27.62 | 2025 | |
| Rigel Pharmaceuticals, INC. | $27.52 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Taiho Oncology, INC. | $19.33 | 2025 | |
| Celgene Corporation | $17.98 | 2025 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $16.52 | 2025 | Tazverik |
| Legend Biotech USA INC. | $15.50 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Acrotech Biopharma INC. | $11.97 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Mukherjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.